The global Non-small Cell Lung Cancer Drugs market was valued at US$ 31,614.8 million in 2023 and is projected to reach US$ 68,888.6 million by 2029, at a CAGR of 9.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Drugs. This report contains market size and forecasts of Non-small Cell Lung Cancer Drugs in global, including the following market information:
- Global Non-small Cell Lung Cancer Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2023 (%)
The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing.
We surveyed the Non-small Cell Lung Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-small Cell Lung Cancer Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Type, 2023 (%)
- Biologics
- Small Molecule Targeted Therapy
- Chemotherapy
- Other
Global Non-small Cell Lung Cancer Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Application, 2023 (%)
- Lung Adenocarcinoma
- Squamous Cell Lung Carcinoma
- Large-cell Lung Carcinoma
Global Non-small Cell Lung Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Non-small Cell Lung Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Non-small Cell Lung Cancer Drugs revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-small Cell Lung Cancer Drugs, market overview.
Chapter 2: Global Non-small Cell Lung Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments
by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments
by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-small Cell Lung Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-small Cell Lung Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-small Cell Lung Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-small Cell Lung Cancer Drugs Overall Market Size
2.1 Global Non-small Cell Lung Cancer Drugs Market Size: 2022 VS 2030
2.2 Global Non-small Cell Lung Cancer Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-small Cell Lung Cancer Drugs Players in Global Market
3.2 Top Global Non-small Cell Lung Cancer Drugs Companies Ranked by Revenue
3.3 Global Non-small Cell Lung Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-small Cell Lung Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-small Cell Lung Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-small Cell Lung Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-small Cell Lung Cancer Drugs Market Size Markets, 2022 & 2030
4.1.2 Biologics
4.1.3 Small Molecule Targeted Therapy
4.1.4 Chemotherapy
4.1.5 Other
4.2 By Type - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Non-small Cell Lung Cancer Drugs Revenue, 2018-2023
4.2.2 By Type - Global Non-small Cell Lung Cancer Drugs Revenue, 2024-2030
4.2.3 By Type - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-small Cell Lung Cancer Drugs Market Size, 2022 & 2030
5.1.2 Lung Adenocarcinoma
5.1.3 Squamous Cell Lung Carcinoma
5.1.4 Large-cell Lung Carcinoma
5.2 By Application - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Non-small Cell Lung Cancer Drugs Revenue, 2018-2023
5.2.2 By Application - Global Non-small Cell Lung Cancer Drugs Revenue, 2024-2030
5.2.3 By Application - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-small Cell Lung Cancer Drugs Market Size, 2022 & 2030
6.2 By Region - Global Non-small Cell Lung Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Non-small Cell Lung Cancer Drugs Revenue, 2018-2023
6.2.2 By Region - Global Non-small Cell Lung Cancer Drugs Revenue, 2024-2030
6.2.3 By Region - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-small Cell Lung Cancer Drugs Revenue, 2018-2030
6.3.2 US Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.3.3 Canada Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.3.4 Mexico Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, 2018-2030
6.4.2 Germany Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.3 France Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.4 U.K. Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.5 Italy Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.6 Russia Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.4.8 Benelux Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, 2018-2030
6.5.2 China Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.5.3 Japan Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.5.4 South Korea Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.5.6 India Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-small Cell Lung Cancer Drugs Revenue, 2018-2030
6.6.2 Brazil Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.6.3 Argentina Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, 2018-2030
6.7.2 Turkey Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.7.3 Israel Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
6.7.5 UAE Non-small Cell Lung Cancer Drugs Market Size, 2018-2030
7 Non-small Cell Lung Cancer Drugs Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Major Product Offerings
7.1.4 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Company Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.3 Eli Lilly and Company
7.3.1 Eli Lilly and Company Company Summary
7.3.2 Eli Lilly and Company Business Overview
7.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Major Product Offerings
7.3.4 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Eli Lilly and Company Key News & Latest Developments
7.4 F. Hoffmann-La Roche Ltd
7.4.1 F. Hoffmann-La Roche Ltd Company Summary
7.4.2 F. Hoffmann-La Roche Ltd Business Overview
7.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Major Product Offerings
7.4.4 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 F. Hoffmann-La Roche Ltd Key News & Latest Developments
7.5 Merck & Co., Inc.
7.5.1 Merck & Co., Inc. Company Summary
7.5.2 Merck & Co., Inc. Business Overview
7.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Major Product Offerings
7.5.4 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 Merck & Co., Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-small Cell Lung Cancer Drugs Market Opportunities & Trends in Global Market
Table 2. Non-small Cell Lung Cancer Drugs Market Drivers in Global Market
Table 3. Non-small Cell Lung Cancer Drugs Market Restraints in Global Market
Table 4. Key Players of Non-small Cell Lung Cancer Drugs in Global Market
Table 5. Top Non-small Cell Lung Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-small Cell Lung Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-small Cell Lung Cancer Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-small Cell Lung Cancer Drugs Product Type
Table 9. List of Global Tier 1 Non-small Cell Lung Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-small Cell Lung Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-small Cell Lung Cancer Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-small Cell Lung Cancer Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2024-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Non-small Cell Lung Cancer Drugs Product Offerings
Table 32. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Company Summary
Table 35. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offerings
Table 36. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol-Myers Squibb Company Key News & Latest Developments
Table 38. Eli Lilly and Company Company Summary
Table 39. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offerings
Table 40. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Eli Lilly and Company Key News & Latest Developments
Table 42. F. Hoffmann-La Roche Ltd Company Summary
Table 43. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offerings
Table 44. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. F. Hoffmann-La Roche Ltd Key News & Latest Developments
Table 46. Merck & Co., Inc. Company Summary
Table 47. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offerings
Table 48. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Merck & Co., Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-small Cell Lung Cancer Drugs Segment by Type in 2022
Figure 2. Non-small Cell Lung Cancer Drugs Segment by Application in 2022
Figure 3. Global Non-small Cell Lung Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-small Cell Lung Cancer Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-small Cell Lung Cancer Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-small Cell Lung Cancer Drugs Revenue in 2022
Figure 8. By Type - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 16. US Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 28. China Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-small Cell Lung Cancer Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-small Cell Lung Cancer Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
